Rivian founder and CEO RJ Scaringe has transferred a portion of his ownership stake and voting power as part of a newly-settled divorce proceeding, according to a regulatory filing. Scaringe moved about 4 million in shares and 6 million in options to his ex-wife, Meagan Scaringe, on July 9 as part of the settlement, the filing shows. At Rivian’s current stock price, those shares and options could be worth roughly $130 million, though they have varying strike prices that would affect the total return if sold ...

Key Takeaways CCL shares surged 20.3% on record Q2 margins, triple-digit profit growth and early 2026 target wins. 93% of 2025 capacity is booked at historically high prices, reflecting strong demand and pricing power. CCL raised its fiscal 2025 EPS forecast to $1.97, with adjusted EBITDA projected at $6.9 billion.Shares of Carnival Corporation & plc (CCL) have rallied 20.3% in the past month compared with the Zacks Leisure and Recreation Services industry’s 11.8% growth. Over the same timeframe, the stoc ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.CRISPR Therapeutics currentl ...

核心观点 - 雅培(ABT)即将公布的季度财报预计每股收益为1.25美元，同比增长9.7%，营收预计为110.7亿美元，同比增长6.7% [1] - 过去30天内分析师对雅培每股收益的共识预期下调了0.4%，显示市场对其预期有所调整 [1] - 雅培股价在过去一个月下跌2.7%，而同期标普500指数上涨4%，但公司仍被给予Zacks Rank 2(买入)评级，预计将跑赢大盘 [8][9] 财务指标预测 营收分项预测 - 营养业务净销售额预计为22.4亿美元，同比增长4.3% [4] - 医疗器械-糖尿病护理业务净销售额预计为19.4亿美元，同比增长17.5% [4] - 诊断业务净销售额预计为22.2亿美元，同比增长1% [4] - 成熟药品业务净销售额预计为13.7亿美元，同比增长6.1% [5] 区域分项预测 - 美国诊断业务净销售额预计为8.3219亿美元，同比增长2.5% [5] - 国际诊断业务净销售额预计为13.8亿美元，同比增长0.1% [5] - 国际营养业务净销售额预计为12.6亿美元，同比增长3.5% [6] - 美国营养业务净销售额预计为9.852亿美元，同比增长5.6% [6] 医疗器械细分预测 - 神经调控-国际业务净销售额预计为5347万美元，同比增长4.8% [7] - 节律管理-美国业务净销售额预计为3.1205亿美元，同比增长6.9% [7] - 节律管理-国际业务净销售额预计为3.3464亿美元，同比增长6.2% [8] - 结构性心脏病-美国业务净销售额预计为3.0428亿美元，同比增长17.9% [8] 市场反应与分析 - 财报公布前的盈利预期调整是预测股价短期表现的重要因素 [2] - 除关注整体盈利预期外，分析关键业务指标预测也能提供有价值的信息 [3]

Analysts on Wall Street project that Texas Capital (TCBI) will announce quarterly earnings of $1.28 per share in its forthcoming report, representing an increase of 60% year over year. Revenues are projected to reach $298.24 million, increasing 11.7% from the same quarter last year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.7% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial esti ...

市场表现 - 上周五三大基准指数均收跌 道琼斯工业平均指数下跌1% 标普500指数下跌0.3% 纳斯达克综合指数下跌0.1% [1] - 市场回调源于美国关税威胁 对加拿大、欧盟等地区加征关税引发对经济增长和通胀的担忧 [2] 公司股价表现 - Mogo Inc (MOGO)自5月8日被上调至Zacks Rank 2后股价上涨81.8% 同期标普500指数上涨11.1% [4] - ATI Inc (ATI)自5月6日被上调至Zacks Rank 2后回报率达32.6% 同期标普500指数上涨10.7% [5] - Amarin Corporation (AMRN)自5月12日被上调至Outperform后股价上涨62.6% 同期标普500指数上涨10.5% [8] - European Wax Center (EWCZ)同期上涨49.9% [8] 投资组合表现 - Zacks Rank 1股票组合在2025年5月回报率为+6.51% 超过标普500指数的+4.47% [5] - 该组合2024年回报率为+22.4% 低于标普500指数的+28% [6] - 2023年回报率为+20.65% 低于标普500指数的+24.83% [6] - 自1988年以来 Zacks Rank 1股票组合年化平均回报率为+23.5% 超过标普500指数的+11% [7] 焦点股票表现 - Intellia Therapeutics (NTLA)过去12周上涨53.8% Lam Research Corporation (LRCX)同期上涨49.9% 标普500指数上涨15.7% [11] - Zacks Focus List组合2025年回报率为+8.84% 超过标普500指数的+6.21% [12] - 该组合2024年回报率为+18.41% 低于标普500指数的+25.04% [12] 其他投资组合 - Earnings Certain Admiral Portfolio (ECAP)在2025年一季度回报率为+3.20% 标普500指数下跌4.30% [16] - Earnings Certain Dividend Portfolio (ECDP)在2025年一季度回报率为+5.74% 标普500指数下跌2.41% [20] - Zacks Top 10 Stocks组合2025年回报率为+11.8% 超过标普500指数的+6.2% [22] - 该组合自2012年以来累计回报率达+2,246.8% 远超标普500指数的+502.3% [24]

Key Takeaways HEI is gaining from rising air travel, strong defense funding, and growing aftermarket parts demand. HWM benefits from rising commercial and defense aerospace activity, including strong F-35 program orders. Analysts lift IBKR's EPS estimates 4% amid sales growth from software innovation and global market expansion.Wall Street closed at a record-high level despite facing a turbulent first half of 2025. The second quarter of 2025 was the best quarter for U.S. stocks over the past year. Expecta ...

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another. Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a ...

贸易政策与股市关联性 - 特朗普政府可能因标普500指数(SPX)回升至历史高位(6,259.75)而采取更强硬的关税策略 包括威胁对加拿大征收50%关税并对巴西越南施压[1][5] - 2-3月SPX因全球关税政策暴跌后 4月政府推迟"解放日"关税恰逢SPX较2月峰值下跌20% 显示政策调整与股市表现存在时间关联[2] - 当前SPX突破关键点位(2024年底5,882 大选日5,783 就职日前5,995 2月峰值6,144)可能进一步刺激关税升级[8][9] 市场波动与投资者情绪 - 尽管关税威胁加剧且8月1日截止日临近 但VIX波动率指数跌至16.4 创2月以来新低 显示市场反应平静[7][11] - 30天VIX期货溢价超15%时(当前水平) 历史数据显示未来1-2周SPX平均回报率仅0.01% 显著低于溢价较低时期[12][13] - 主动投资经理协会(NAAIM)乐观指数从年内低点50升至86 SPX成分股空头头寸增加5%至多年高位 反映市场存在分歧[16][18][19] 技术面与潜在支撑位 - SPX若回调 第一支撑位在2月前高6,144 第二支撑位为30日均线(当前6,080 预计周末升至6,130)[20] - 7月期权到期周若SPDR ETF(SPY)收于613-615区间 将导致大量期权合约作废 可能吸引卖盘[21]

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...